← Back to Home

Verge Labs

Private
#Amyotrophic lateral sclerosis (ALS)#Parkinson's disease#Alzheimer's disease#Multiple sclerosis#Other neurology indications

Verge Labs (formerly Verge Genomics) is a frontier AI lab for human disease biology founded in 2015. The company develops world models of patient biology built on proprietary multi-modal human tissue data and partners with drug developers on target discovery, patient stratification, and biomarker prediction across CNS and beyond.

Company Info

Sector: AI / Machine Learning + Drug Discovery
Headquarters: San Francisco, California, USA
Founded: 2015
Website: vergelabs.com/
Funding Round: Series undisclosed (post-pivot 2026)
Total Funding: $130M+ to date

Funding & Investor Relations

Notable Investors

  • Founders Fund
  • ALS Investment Fund
  • BlackRock
  • Eli Lilly (strategic partner)

Upcoming Milestones & Key Dates

2026 H2
Pipeline update

First partnership program target nomination

2027
Financing

Expected Series B / strategic financing

Clinical Development Pipeline

VRG-001 (formerly VRG50635)

Target: PIKfyve kinase inhibitor
Sporadic ALS
Preclinical
Phase 1
Phase 2
Phase 3
Approved

AI-discovered CNS targets (undisclosed)

Target: Multi-modal AI platform
Multiple neurology indications
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Patient stratification AI model

Target: Multi-modal biomarker AI
Neurology clinical trial enrichment
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Alice Zhang

Co-Founder & CEO

Jason Chen

Chief Technology Officer

Robert H. Brown Jr.

Scientific Advisory Board Chair (Neurology)

Careers & Job Openings

See all open roles

Multiple Departments
San Francisco, CA
Apply Now →